A Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia
A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia
Sponsor: BioMarin Pharmaceutical
This PHASE3 trial investigates Achondroplasia and is currently completed. BioMarin Pharmaceutical leads this study, which shows 15 recorded versions since 2016 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
15 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Apr 2022 — Jul 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Apr 2022 [monthly]
Completed PHASE3
▶ Show 10 earlier versions
-
Jun 2020 — Jan 2021 [monthly]
Completed PHASE3
-
Feb 2020 — Jun 2020 [monthly]
Completed PHASE3
-
Jan 2020 — Feb 2020 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Jun 2019 — Jan 2020 [monthly]
Active Not Recruiting PHASE3
-
Feb 2019 — Jun 2019 [monthly]
Active Not Recruiting PHASE3
Status: Enrolling By Invitation → Active Not Recruiting
-
Oct 2018 — Feb 2019 [monthly]
Enrolling By Invitation PHASE3
-
Jul 2018 — Oct 2018 [monthly]
Enrolling By Invitation PHASE3
-
Jun 2018 — Jul 2018 [monthly]
Enrolling By Invitation PHASE3
-
Apr 2018 — Jun 2018 [monthly]
Enrolling By Invitation PHASE3
-
Jul 2017 — Apr 2018 [monthly]
Enrolling By Invitation PHASE3
First recorded
Dec 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- BioMarin Pharmaceutical
For direct contact, visit the study record on ClinicalTrials.gov .